SPA17 and plasma cell myeloma: Previous studies also underline the potential cancer immunogenicity and immunotherapy targeting the role of the SPA17 protein or transcript in various cancers, such as ovarian cancer, esophageal squamous cell carcinoma, and multiple myeloma (54–56).